Quick Answer
Trevi Therapeutics, Inc. reported Earnings Per Share Diluted of $0.32 (loss) per share for the year ending 2025.
- Trevi Therapeutics, Inc. showed an increase of +31.9% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Trevi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $0.49 (loss) per share | Q3 2021: $0.34 (loss) per share | Q1 2022: $0.24 (loss) per share | Q2 2022: $0.14 (loss) per share | Q3 2022: $0.12 (loss) per share | Q1 2023: $0.06 (loss) per share | Q2 2023: $0.07 (loss) per share | Q3 2023: $0.08 (loss) per share | Q1 2024: $0.11 (loss) per share | Q2 2024: $0.12 (loss) per share | Q3 2024: $0.13 (loss) per share | Q1 2025: $0.09 (loss) per share | Q2 2025: $0.09 (loss) per share | Q3 2025: $0.08 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), Trevi Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 78.5%.
- Historical annual values: Fiscal year 2025: $0.32 (loss) per share | Fiscal year 2024: $0.47 (loss) per share | Fiscal year 2023: $0.29 (loss) per share | Fiscal year 2022: $0.45 (loss) per share | Fiscal year 2021: $1.49 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: